基于18F-FDG PET/CT影像组学的Claudin 18.2阳性胃腺癌分层
本研究纳入291例病理确诊胃腺癌患者,回顾性构建术前18F-FDG PET/CT多模态影像组学模型预测CLDN18.2表达,训练集204例、验证集87例。CLDN18.2阳性肿瘤呈低代谢表型,联合模型训练集AUC 0.926(95%CI 0.891-0.961),验证集AUC 0.765(95%CI 0.665-0.865),优于单模态模型。
要点
- CLDN18.2阳性胃腺癌呈低代谢表型,SUVmax(P=0.012)与SUVmean(P<0.001)显著低于阴性肿瘤。
- PET/CT多模态影像组学联合模型预测CLDN18.2表达,验证集AUC 0.765(95%CI 0.665-0.865)。
- SHAP分析显示PET影像组学特征与血清CEA为最具影响力的预测因子。
核心结论
- 基于18F-FDG PET/CT的多模态影像组学模型可作为预测胃腺癌CLDN18.2表达的无创工具。
- 研究验证了CLDN18.2阳性肿瘤的低代谢特性,提示影像组学方法可有效补充传统活检用于患者分层。
研究设计与样本
- 回顾性研究纳入291例病理确诊胃腺癌且术前行18F-FDG PET/CT的患者,随机分为训练集204例和独立验证集87例。
主要发现
- CLDN18.2阳性肿瘤SUVmax显著低于阴性肿瘤(P=0.012),SUVmean亦显著降低(P<0.001)。
- 联合多模态模型训练集AUC为0.926(95%CI 0.891-0.961),验证集AUC为0.765(95%CI 0.665-0.865),持续优于单模态模型。
- SHAP分析显示PET影像组学特征和血清CEA为最具影响力的预测因子,证实代谢活性与CLDN18.2表达呈负相关。
关键数值与推荐
- 在五种机器学习算法中,AdaBoost被确定为最优模型。
- 特征选择采用mRMR算法和LASSO回归,影像组学 signature(Rad-score)基于XGBoost构建并与临床变量整合。
临床怎么用
- 该模型可无创预测胃腺癌CLDN18.2表达,有望辅助活检进行患者分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to develop and validate a non-invasive, multimodal radiomics model based on preoperative 1⁸F-FDG PET/CT to predict CLDN18.2 expression in gastric adenocarcinoma (GAC), addressing the limitations of intratumoral heterogeneity and invasiveness associated with endoscopic biopsies. METHODS: This retrospective study enrolled 291 patients with pathologically confirmed GAC who underwent preoperative 1⁸F-FDG PET/CT. The cohort was randomly divided into a training set (n = 204) and an independent validation set (n = 87). High-dimensional radiomic features were extracted from PET and CT images. Feature selection was performed using the minimum redundancy maximum relevance (mRMR) algorithm and LASSO regression. A radiomics signature (Rad-score) was constructed using XGBoost and integrated with clinical variables. Among five machine learning algorithms evaluated, AdaBoost was identified as the optimal model. Performance was assessed via receiver operating characteristic (ROC) analysis, and interpretability was visualized using SHapley Additive exPlanations (SHAP). RESULTS: CLDN18.2-positive tumors exhibited a distinct hypometabolic phenotype, characterized by significantly lower SUVmax (P = 0.012) and SUVmean (P < 0.001) compared to negative tumors. The combined multimodal model demonstrated superior discrimination, achieving an AUC of 0.926 (95% CI: 0.891-0.961) in the training cohort and 0.765 (95% CI: 0.665-0.865) in the validation cohort, consistently outperforming single-modality models. SHAP analysis highlighted PET-derived radiomic features and serum CEA as the most influential predictors, confirming the inverse correlation between metabolic activity and CLDN18.2 expression. CONCLUSION: The developed 1⁸F-FDG PET/CT-based multimodal radiomics model serves as an effective, non-invasive tool for predicting CLDN18.2 expression in GAC. The study validates the hypometabolic nature of CLDN18.2-positive tumors, suggesting this radiomics approach can effectively complement traditional biopsy methods for patient stratification.
引用
- Sun C, Zhang J, Song J, et al. Imaging-based stratification of Claudin 18.2-positive gastric adenocarcinoma using 18F-FDG PET/CT radiomics. Eur J Nucl Med Mol Imaging. 2026. PMID: 41942650. doi:10.1007/s00259-026-07877-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。